Print

News

  • IGBA urgent recommendations to keep medicine supply chains flowing (27 March 2020)

    The current operating model of medicines supply requires transparent global collaboration to provide access to medicines for patients around the world. Read More
  • COVID-19 / Urgent call to governments - Air freight must reopen for critical medicines and supplies for their manufacture (March 2020)

    The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today requested urgent action by governments and pharmaceutical supply chain stakeholders to reopen air freight routes and ensure patients around the globe can Read More
  • COVID-19: Critical to keep the supply chain of essential medicines manufacturing operating at full capacity (March 2020)

    IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today calls upon the global policy leaders and governments to do everything in their power to keep the manufacturing operations and the supply Read More
  • Hanan Sboul takes over the position of IGBA Chair (January 2020)

    IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Hanan Sboul, Secretary General of the Jordanian Association of Pharmaceutical Manufacturers, is taking over the position of IGBA Chair for Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13

Print

Vision and Mission

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.

Print

The IGBA

In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).

Annual Conference - Warsaw 2019

Annual Conference - Budapest 2018

Annual Conference - Lisboa 2017

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

Telephone: +32 (0)2 5346607 (S. Kox)
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site